| Objective: To estimate the effect of statin on clinical events, cardiac function and cardiac inflammation in patients with chronic heart failure.Methods: Pub Med, EMBASE and Cochrane library were searched with Me SH keywords“heart failure”, “hydroxymethylglutaryl-CoA reductase inhibitors” and “randomized controlled trial” combined with key words and date were analyzed by Review Manager 5.3 and stata 13.0.Results: A total of 21 publications were included. Meta-analysis results showed that(1)statin could decrease the risk of hospitalization for worsening heart failure[ RR 0.84(0.70,0.99)P = 0.04] as well as all-cause death[RR 0.58(0.41,0.82) P =0.002](lipophilic statin only),but, could not decrease cardiovascular death risk[RR 0.97(0.90,1.04) P =0.37];(2)statin could improve left ventricular ejection(LVEF)[MD 2.89(1.37, 4.41) P = 0.0002], and reduce the level of BNP[SMD-0.26(-0.44,-0.07) P = 0.006];(3)statin could decrease the level of hs C RP[SMD-0.39(-0.58,-0.20) P <0.0001]and TNF-α[SMD 0.77(-1.07,-0.48) P <0.00001];(4)Further subgroup-analysis revealed that patients younger than 65-year old or with ≥30% baseline LVEF benefitted more from statin and patients benefitted more from lipophilic statin than hydrophilic statin.Conclusion: Heart failure patients could benefit from statin. While the effect of statin was affected by the age, the baseline LVEF and the type of statin. |
PDF Full Text Request